无病生存期作为人表皮生长因子受体2阳性早期乳腺癌辅助曲妥珠单抗治疗最长1年试验中总生存期的替代终点:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项随机对照试验(n=21480例),评估人表皮生长因子受体2阳性早期乳腺癌辅助抗人表皮生长因子受体2抗体治疗中无病生存期对总生存期的替代性。患者水平相关性强度为rs=0.90(95%CI 0.89-0.90),试验水平R²为0.75(95%CI 0.50-1.00),替代阈值效应范围为0.56至0.81。作者认为在这些试验中继续使用无病生存期作为总生存期的替代终点是合适的。
要点
- 患者水平无病生存期与总生存期强相关(rs=0.90,95%CI 0.89-0.90)。
- 试验水平无病生存期与总生存期风险比关联R²为0.75(95%CI 0.50-1.00)。
- 替代阈值效应范围为0.56至0.81,取决于未来试验的预期死亡数。
核心结论
- 这些发现提示,在人表皮生长因子受体2阳性早期乳腺癌试验中继续使用无病生存期作为总生存期的替代终点是合适的。
研究设计与样本
- 系统综述与荟萃分析,检索截至2016年9月的已发表和未发表随机对照试验,纳入8项试验(n=21480例患者),产生12个对比。
- 纳入标准为治疗人表皮生长因子受体2阳性早期乳腺癌,至少一组计划接受抗人表皮生长因子受体2抗体治疗12个月,且至少一个对照臂为不含抗体的化疗、较低总剂量或较短疗程的抗体、或单纯观察。
- 分析单位为对比:两组试验产生一个对比,多于两组的试验产生一个以上对比。
- 排除入组复发、转移或非浸润性疾病患者的试验,以及仅测试新辅助治疗的试验。
主要发现
- 患者水平无病生存期与总生存期相关性强度为rs=0.90(95%CI 0.89-0.90)。
- 试验水平无病生存期与总生存期风险比关联R²为0.75(95%CI 0.50-1.00)。
- 按淋巴结状态和激素受体状态定义的亚组结果定性相似。
- 根据未来试验的预期死亡数,替代阈值效应范围为0.56至0.81(基于全集)。
关键数值与推荐
- 患者水平相关性采用Spearman相关系数(rs)衡量,试验水平风险比关联采用R²衡量。
- 替代阈值效应定义为在未来试验中统计预测总生存期风险比小于1.00的无病生存期最大风险比。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究的关键局限性是其结果依赖于所纳入的试验以及存在一个离群试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although frequently used as a primary endpoint, disease-free survival has not been validated as a surrogate for overall survival in early breast cancer. We investigated this surrogacy in the adjuvant setting of treatment with anti-HER2 antibodies. METHODS: In a systematic review and meta-analysis, we identified published and non-published randomised controlled trials with completed accrual and available disease-free survival and overall survival results for the intention-to-treat population as of September 2016. Bibliographic databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials), clinical trial registries (Clinicaltrials.gov, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform, and PharmNet.Bund), and trial registries from relevant pharmaceutical companies were searched. Eligibility for treatment of HER2-positive early breast cancer required at least one group to have an anti-HER antibody treatment (ie, trastuzumab, pertuzumab, or trastuzumab emtansine) planned for 12 months, and at least one control arm with chemotherapy without the antibody, a lower total dose or duration of the antibody, or observation alone. Units of analysis were contrasts: two-group trials gave rise to one contrast, whereas trials with more than two groups gave rise to more than one contrast. We excluded trials enrolling patients with recurrent, metastatic, or non-invasive disease, and those testing neoadjuvant therapy exclusively. Our primary objective was to estimate patient-level and trial-level correlations between disease-free survival and overall survival. We measured the association between disease-free survival and overall survival using Spearman's correlation coefficient (rs), and the association between hazard ratios (HRs) for disease-free survival and overall survival using R2. We computed the surrogate threshold effect, the maximum HR for disease-free survival that statistically predicts an HR for overall survival less than 1·00 in a future trial. FINDINGS: Eight trials (n=21 480 patients) gave rise to a full set (12 contrasts). Patient-level associations between disease-free and overall survival were strong (rs=0·90 [95% CI 0·89-0·90]). Trial-level associations gave rise to values of R2 of 0·75 (95% CI 0·50-1·00) for the full set. Subgroups defined by nodal status and hormone receptor status yielded qualitatively similar results. Depending on the expected number of deaths in a future trial, the surrogate threshold effects ranged from 0·56 to 0·81, based on the full set. INTERPRETATION: These findings suggest that it is appropriate to continue to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive, early breast cancer. The key limitation of this study is the dependence of its results on the trials included and on the existence of an outlying trial. FUNDING: Roche Pharma AG.
引用
- Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019. PMID: 30709633. doi:10.1016/S1470-2045(18)30750-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。